Mitral transcatheter edge-to-edge repair in ischemic vs non-ischemic functional mitral regurgitation: differential patterns of reverse remodeling and clinical recovery

Read full text Summarise with VIRAT
Authors: G Papadopoulos, Ilias Ninios, Sotirios Evangelou, A Ioannides, Vlasis N. Ninios
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background/Introduction Mitral transcatheter edge-to-edge repair (M-TEER) has emerged as an established therapy for functional mitral regurgitation (FMR). However, ischemic and non-ischemic FMR differ in etiology, remodeling patterns, and prognostic implications. Purpose This study aimed to compare the clinical and echocardiographic effects of TEER in these two patient subsets. Methods We prospectively analyzed 92 consecutive patients with symptomatic (NYHA class III–IV) moderate-to-severe (3+) or severe (4+) FMR who underwent M- TEER between January 2022 and December 2024. Patients were stratified into ischemic (n=58, 63.0%) and non-ischemic (n=34, 37.0%) groups. Procedural success was defined as residual MR ≤2+ without major adverse events at hospital discharge. Clinical outcomes, Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OS), and echocardiographic parameters were assessed at baseline, 30 days, and 1 year. Results Procedural success was achieved in all patients (100%). At 1 year, heart failure hospitalization occurred in 11 patients (12.0%), while all-cause mortality was observed in 9 patients (9.8%). Severe MR was abolished in all cases by 30 days, with MR ≤2+ maintained in 98.9% at 1 year (Figure 1). Mild MR or less was documented in 36.0% of patients at 1 year, compared to none at baseline. Functional status improved markedly: 100% of patients were in NYHA class I–II at 30 days, with 98.9% sustaining this benefit at 1 year; the proportion of asymptomatic individuals increased from 38% at 30 days to 45% at 1 year (Figure 1). KCCQ-OS scores improved from 48 ± 20 at baseline to 62 ± 12 at 30 days and 66 ± 15 at 1 year (p

Fields of Study & Subjects

Cardiac Valve Diseases and Treatments Cardiac Structural Anomalies and Repair Cardiac Arrhythmias and Treatments

Publication details

Journal / source
European Heart Journal Supplements
Volume
28
Issue
Supplement_3
Pages
suag056.057
Publication date
1 March 2026
Language
EN